The Illinois Wellness Insider
SEE OTHER BRANDS

Informing on health and wellness news in Illinois

The Illinois Wellness Insider: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.

Press releases published on July 22, 2025

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July …

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the first patient has been dosed in the Phase 2 portion of the Phase 1/2 BIPAVE-001 trial ( …

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics Announces Leadership Transition

Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including …

SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices

SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices

Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot …

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) …

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) --  ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in …

Telix Reports $204M Revenue, Up 63% YOY

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All …

Llusern Scientific Announces Key Appointments to Strengthen its Executive Team

Llusern Scientific Announces Key Appointments to Strengthen its Executive Team

CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of Bob Yang as Chief Medical Officer (CMO), Maddy Kennedy as Chief Financial Officer (CFO), and Mark …

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights

San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD …

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, …

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder

KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, …

Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies

Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the signing of a Memorandum of Understanding ( …

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly …

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The …

Communiqué de presse : Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires

Communiqué de presse : Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires

Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires Paris, le 22 juillet 2025. Sanofi annonce aujourd'hui la conclusion d'un accord pour l'acquisition de Vicebio Ltd (« Vicebio »), une société de biotechnologie privée dont le siège …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions